2026 ICD-10-CM Diagnosis Code T39.395SAdverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T39.395S is a billable ICD-10-CM diagnosis code for adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T39.395S.
Present on Admission (POA)Billing
T39.395S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acemetacin adverse reaction
- Acquired pancytopenia
- Adverse reaction to diclofenac sodium
- Adverse reaction to fenbufen
- Adverse reaction to mefenamic acid
- Adverse reaction to piroxicam
- Allergic contact dermatitis caused by drug in contact with skin
- Allergic reaction caused by analgesic
- Allergic reaction caused by nonsteroidal antiinflammatory agent
- Anaphylaxis caused by non-steroidal anti-inflammatory agent
- Delayed photoallergic dermatitis
- Diclofenac adverse reaction
- Drug-induced anaphylaxis
- Drug-induced angioedema-urticaria
- Drug-induced colitis
- Drug-induced enteritis of intestine
- Duodenal ulcer caused by bacterium
- Duodenal ulcer caused by drug
- Duodenal ulcer caused by Helicobacter pylori
- Duodenal ulcer caused by Helicobacter pylori and non-steroidal anti-inflammatory agent
- Duodenal ulcer caused by non-steroidal anti-inflammatory drug
- Etodolac adverse reaction
- Felbinac adverse reaction
- Gastric ulcer caused by bacterium
- Gastric ulcer caused by drug
- Gastric ulcer caused by Helicobacter pylori
- Gastric ulcer caused by Helicobacter pylori and non-steroidal anti-inflammatory agent
- Gastric ulcer caused by non-steroidal anti-inflammatory drug in therapeutic use
- Gastritis medicamentosa
- Indomethacin adverse reaction
- Indomethacin embryofetopathy
- Nabumetone adverse reaction
- Non-allergic anaphylaxis caused by drug
- Non-allergic anaphylaxis caused by non steroidal anti-inflammatory drug
- Non-steroidal anti-inflammatory drug adverse reaction
- Non-steroidal anti-inflammatory drug-induced colitis
- Non-steroidal anti-inflammatory drug-induced enteropathy
- NSAID-associated gastropathy
- NSAID-induced angioedema-urticaria
- Pancytopenia caused by medication
- Pancytopenia caused by non-steroidal anti-inflammatory agent
- Photoallergic contact dermatitis due to non-steroidal anti-inflammatory drug
- Photoallergic dermatitis
- Sulindac adverse reaction
- Tenoxicam adverse reaction
- Tolmetin adverse reaction
- Urticaria medicamentosa
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Diclofenac
a non-steroidal anti-inflammatory agent (nsaid) with antipyretic and analgesic actions. it is primarily available as the sodium salt.Etodolac
a non-steroidal anti-inflammatory agent and cyclooxygenase-2 (cox-2) inhibitor with potent analgesic and anti-arthritic properties. it has been shown to be effective in the treatment of osteoarthritis; rheumatoid arthritis; ankylosing spondylitis; and in the alleviation of postoperative pain (pain, postoperative).Flufenamic Acid
an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. it is used in musculoskeletal and joint disorders and administered by mouth and topically. (from martindale, the extra pharmacopoeia, 30th ed, p16)Indomethacin
a non-steroidal anti-inflammatory agent (nsaid) that inhibits cyclooxygenase, which is necessary for the formation of prostaglandins and other autacoids. it also inhibits the motility of polymorphonuclear leukocytes.Meclofenamic Acid
a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. it also inhibits prostaglandin biosynthesis.Mefenamic Acid
a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. it is an inhibitor of cyclooxygenase.Nabumetone
a butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (cox2) inhibitor that is used in the management of pain associated with osteoarthritis and rheumatoid arthritis.Piroxicam
a cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (nsaid) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. its long half-life enables it to be administered once daily.Sulindac
a sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active nsaid analgesic. specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. this helps to maintain constant blood levels with reduced gastrointestinal side effects.Tolmetin
a non-steroidal anti-inflammatory agent (anti-inflammatory agents, non-steroidal) similar in mode of action to indomethacin.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T39.395S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T39.395SOverview
Is T39.395S a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T39.395S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID] itself has resolved, not the original event.
What MS-DRG does T39.395S group to?
On inpatient claims, adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T39.395S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T39.395S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
